Latest News

Archive 2005

12.22.05	Pharmagap Announces Approval For And Issuance Of Series 3 Notes
11.23.05	MOU Signed with Leading U.S. Cancer Institute
10.31.05	PharmaGap Sets Pricing Terms For Private Placement
09.30.05	PharmaGap Announces SC Stormont Holdings To Extend Date For Mandatory Conversion Of Note
09.20.05	PharmaGap Retains Leading Investor Relations Firm
09.07.05	PharmaGap Completes Issuance of Convertible Secured Promissory Note
08.29.05	PharmaGap Announces Closing of Convertible Secured Promissory Note Financing
08.11.05	PharmagGap Announces Licensing Discussions,Funding Program, And Commencement Of Efficacy Testing On Human Cancers In Mice
06.22.05	PharmaGap Update At Annual Meeting
05.20.05	PharmaGap Equity Increase And Extension Of Selling Period
05.17.05	PharmaGap Completes Acute Toxicity Tests For Lead
05.09.05	Stormont To Invest In PharmaGap Equity Issue
05.09.05	PharmaGap Announces Excellent Results Of Acute Toxicity Tests For Lead Cancer Drug Early Discussions With Potential Licensees
04.26.05	PharmaGap Reports Breast Cancer And Multi-Drug Resistance
04.01.05	Re-Priced Director Options
03.30.05	PharmaGap Approved By The National Research Council To Begin Small Animal Testing Program
03.24.05	Rod Bryden Appointed Chairman Of The Board Of PharmaGap
03.23.05	PharmaGap Success Reported In Demonstrating Effectiveness Of Drug Compound On Non Small Cell Lung Cancer Cells In Laboratory Testing
03.08.05	PharmaGap Reports Sharply Lower Loss for 2004, Encouraging Results in Drug Development
01.16.05	Pharmagap Closes On Additional Tranche Of Series 3 Notes
01.04.05	PharmaGap Receives Final TSX-V Acceptance For Its Private Placement